Johnson & Johnson Family of Companies
United States
2690 articles about Johnson & Johnson Family of Companies
-
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
1/24/2024
Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium (San Francisco, January 25-27), highlighting the Company's commitment to transform the science of genitourinary (GU) cancers.
-
An FDA advisory committee will meet to review J&J and Legend Biotech’s supplemental BLA for Carvykti for the treatment of relapsed or refractory multiple myeloma patients who have undergone at least one prior line of therapy.
-
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
1/23/2024
Johnson & Johnson announced results for fourth-quarter and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer.
-
Johnson & Johnson exceeded fourth-quarter earnings estimates, reporting nearly $21.4 billion in revenue, as its pharma business faces a patent cliff with Stelara competition entering the market.
-
Although the FDA did not outright say there is a causal secondary malignancy relationship, it asked BMS, Gilead, J&J and Novartis to add warnings to the labels of six CAR-T therapies noting the potential risks.
-
TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study
1/22/2024
Johnson & Johnson today announced that TREMFYA® (guselkumab) demonstrated rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory pigmentation at 16 weeks.
-
Johnson & Johnson’s small molecule FGFR kinase inhibitor is now indicated for patients with susceptible FGFR3 mutations who progressed after at least one line of systemic therapy.
-
U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
1/19/2024
Johnson & Johnson announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application for BALVERSA® for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible fibroblast growth factor receptor 3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
-
The pharma execs may be served with subpoenas to appear before the Senate health committee to explain why their products are much more expensive in the U.S. than in other countries, according to chairman Sen. Bernie Sanders.
-
Brand pharmas not only leverage ancillary patents but sometimes hide or misrepresent information to the U.S. patent office in order to extend market exclusivity and high prices.
-
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
1/8/2024
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
-
Ambrx Announces Sale to Johnson & Johnson
1/8/2024
Ambrx Biopharma, Inc., or Ambrx, announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion.
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024
1/2/2024
Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the first quarter of 2024 of $1.19 per share on the company’s common stock.
-
Johnson & Johnson and Genmab revealed the first data from a Phase III study of a Darzalex Faspro-based quadruplet therapy in patients with transplant-eligible newly diagnosed multiple myeloma.
-
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
12/12/2023
Johnson & Johnson announced an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ in patients with relapsed or refractory multiple myeloma showed that patients treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy as well as BCMA and anti-Fc receptor-like protein 5 bispecific antibodies, after TALVEY™ treatment.
-
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
12/12/2023
Johnson & Johnson announced new patient-reported outcomes from the Phase 3 CARTITUDE-4 study of CARVYKTI® demonstrated clinically meaningful improvements in health-related quality of life and meaningful reductions in disease-specific symptoms according to multiple PRO measures in the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy.
-
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter 2023 Results
12/11/2023
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, January 23rd to review fourth-quarter results.
-
Under an agreement with Johnson & Johnson’s Actelion Pharmaceuticals, the rights to the multiple sclerosis drug Ponvory in the U.S. and Canada will be transferred to Vanda Pharmaceuticals.
-
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
12/5/2023
Johnson & Johnson is hosting a meeting with the investment community at the New York Stock Exchange to present the Company’s overarching strategy, its diverse and robust Innovative Medicine and MedTech pipelines and long-term financial outlook.
-
Ten of the anticipated assets have the potential to deliver $5 billion or more in peak year sales, while another 15 of the candidates have a $1 billion to $5 billion PYS potential, according to Johnson & Johnson.